세계의 발작성 야간 헤모글로빈뇨증 치료제 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Paroxysmal Nocturnal Hemoglobinuria Drug Market is presumed to reach the market size of nearly USD 14.74 BN by 2030 from USD 5.71 BN in 2022 with a CAGR of 12.6% under the study period 2023 - 2030.

Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs are medications designed to treat and manage Paroxysmal Nocturnal Hemoglobinuria, a rare and potentially life-threatening blood disorder. It is characterized by the abnormal breakdown of red blood cells, leading to hemoglobin in the urine, blood clots, and an increased risk of complications such as anemia, fatigue, and organ damage.

MARKET DYNAMICS

The rarity of PNH and its classification as a rare disease contribute to an unmet medical need, encouraging research and development in the field. Advances in biopharmaceuticals, particularly monoclonal antibodies like eculizumab (Soliris), have transformed PNH treatment. Orphan drug designation for PNH drugs, driven by the condition's rarity, provides incentives for pharmaceutical companies. Increased awareness and diagnostic capabilities lead to more PNH diagnoses, boosting the demand for effective drugs. The global aging population, with PNH more prevalent in adults, further amplifies market potential. Strategic collaborations and partnerships accelerate drug development, while healthcare infrastructure and reimbursement policies influence patient access. Ongoing clinical trials and research initiatives contribute to market growth by exploring new therapeutic options.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of paroxysmal nocturnal hemoglobinuria drug. The growth and trends of paroxysmal nocturnal hemoglobinuria drug industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the paroxysmal nocturnal hemoglobinuria drug market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

• Medication
• Stem Cell Transplant
• Blood Transfusion

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Paroxysmal Nocturnal Hemoglobinuria Drug market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Paroxysmal Nocturnal Hemoglobinuria Drug market include Alexion Pharmaceuticals, Takeda Pharmaceutical Company Limited (Shire Plc), Akari Therapeutics, Apellis Pharmaceuticals, Ra Pharmaceuticals, Achillion Pharmaceuticals, Amgen Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Treatment
  • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET ANALYSIS BY TREATMENT

• 5.1 Overview by Treatment
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Treatment
• 5.4 Medication Historic and Forecast Sales by Regions
• 5.5 Stem Cell Transplant Historic and Forecast Sales by Regions
• 5.6 Blood Transfusion Historic and Forecast Sales by Regions

6 . GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET ANALYSIS BY GEOGRAPHY

• 6.1. Regional Outlook
• 6.2. Introduction
• 6.3. North America Sales Analysis
  • 6.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.3.2. North America By Segment Sales Analysis
  • 6.3.3. North America By Country Sales Analysis
  • 6.3.4. United State Sales Analysis
  • 6.3.5. Canada Sales Analysis
  • 6.3.6. Mexico Sales Analysis
• 6.4. Europe Sales Analysis
  • 6.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.4.2. Europe by Segment Sales Analysis
  • 6.4.3. Europe by Country Sales Analysis
  • 6.4.4. United Kingdom Sales Analysis
  • 6.4.5. France Sales Analysis
  • 6.4.6. Germany Sales Analysis
  • 6.4.7. Italy Sales Analysis
  • 6.4.8. Russia Sales Analysis
  • 6.4.9. Rest Of Europe Sales Analysis
• 6.5. Asia Pacific Sales Analysis
  • 6.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.5.2. Asia Pacific by Segment Sales Analysis
  • 6.5.3. Asia Pacific by Country Sales Analysis
  • 6.5.4. China Sales Analysis
  • 6.5.5. India Sales Analysis
  • 6.5.6. Japan Sales Analysis
  • 6.5.7. South Korea Sales Analysis
  • 6.5.8. Australia Sales Analysis
  • 6.5.9. South East Asia Sales Analysis
  • 6.5.10. Rest Of Asia Pacific Sales Analysis
• 6.6. Latin America Sales Analysis
  • 6.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.6.2. Latin America by Segment Sales Analysis
  • 6.6.3. Latin America by Country Sales Analysis
  • 6.6.4. Brazil Sales Analysis
  • 6.6.5. Argentina Sales Analysis
  • 6.6.6. Peru Sales Analysis
  • 6.6.7. Chile Sales Analysis
  • 6.6.8. Rest of Latin America Sales Analysis
• 6.7. Middle East & Africa Sales Analysis
  • 6.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.7.2. Middle East & Africa by Segment Sales Analysis
  • 6.7.3. Middle East & Africa by Country Sales Analysis
  • 6.7.4. Saudi Arabia Sales Analysis
  • 6.7.5. UAE Sales Analysis
  • 6.7.6. Israel Sales Analysis
  • 6.7.7. South Africa Sales Analysis
  • 6.7.8. Rest Of Middle East And Africa Sales Analysis

7 . COMPETITIVE LANDSCAPE OF THE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG COMPANIES

• 7.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Competition
• 7.2. Partnership/Collaboration/Agreement
• 7.3. Merger And Acquisitions
• 7.4. New Product Launch
• 7.5. Other Developments

8 . COMPANY PROFILES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG INDUSTRY

• 8.1. Company Share Analysis
• 8.2. Market Concentration Rate
• 8.3. Alexion Pharmaceuticals
  • 8.3.1. Company Overview
  • 8.3.2. Company Revenue
  • 8.3.3. Products
  • 8.3.4. Recent Developments
• 8.4. Takeda Pharmaceutical Company Limited (Shire Plc)
  • 8.4.1. Company Overview
  • 8.4.2. Company Revenue
  • 8.4.3. Products
  • 8.4.4. Recent Developments
• 8.5. Akari Therapeutics
  • 8.5.1. Company Overview
  • 8.5.2. Company Revenue
  • 8.5.3. Products
  • 8.5.4. Recent Developments
• 8.6. Apellis Pharmaceuticals
  • 8.6.1. Company Overview
  • 8.6.2. Company Revenue
  • 8.6.3. Products
  • 8.6.4. Recent Developments
• 8.7. Ra Pharmaceuticals
  • 8.7.1. Company Overview
  • 8.7.2. Company Revenue
  • 8.7.3. Products
  • 8.7.4. Recent Developments
• 8.8. Achillion Pharmaceuticals
  • 8.8.1. Company Overview
  • 8.8.2. Company Revenue
  • 8.8.3. Products
  • 8.8.4. Recent Developments
• 8.9. Amgen Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Revenue
  • 8.9.3. Products
  • 8.9.4. Recent Developments
• 8.10. Regeneron Pharmaceuticals Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Revenue
  • 8.10.3. Products
  • 8.10.4. Recent Developments
• 8.11. F. Hoffmann-La Roche AG.
  • 8.11.1. Company Overview
  • 8.11.2. Company Revenue
  • 8.11.3. Products
  • 8.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies